Genetic Biomarkers for Risk of CLL Progression among high-count MBLs

$2.24M USD

Funder	NATIONAL CANCER INSTITUTE
Recipient Organization	Mayo Clinic Rochester
Country	United States
Start Date	Jan 01, 2021
End Date	Dec 31, 2022
Duration	729 days
Number of Grantees	2
Roles	Co-Investigator; Principal Investigator
Data Source	NIH (US)
Grant ID	`10116792`

Grant Description

Monoclonal B-cell lymphocytosis (MBL) is a precursor state to chronic lymphocytic leukemia (CLL), and one of the most common premalignant conditions.

MBL is present in 5-10% of the adult population over age 40-years (6-12 million U.S. adults) and is an asymptomatic condition that is characterized by an absolute B-cell count